Cite
HARVARD Citation
Hillson, J. et al. (2018). Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. Pharmacology research & perspectives. 6 (1), p. n/a. [Online].